Russia National Registration Window Closes on December 31, 2027

1. Key takeaways

December 31, 2027 is the last defensible date for submitting a medical device registration application under Russian national rules; from January 1, 2028 onward, new registrations proceed only under Union rules. This date was set by the protocol signed on December 29, 2025 (replacing the December 31, 2026 deadline established by the 2021 protocol), and Russia completed ratification through federal law No. 288-ФЗ on August 4, 2026.

The window therefore functions as a hard portfolio constraint rather than a soft planning assumption. Every product intended for the Russian market under national rules must have its application submitted — not approved, submitted — before the closing date. Products that cannot make the window must be re-planned from the outset for the Union pathway, since there is no indication that the deadline will shift again. Treating the date as firm, while monitoring for any further protocol amendments, is the balanced posture.

A recurring question is what exactly counts as meeting the deadline, and the answer deserves precision: the filing must be accepted as submitted before the closing date, with the dossier in a state that allows the procedure to run. A submission made in late December 2027 with predictable deficiency findings does not preserve the national option in any meaningful sense, because remediation beyond the window has no procedural home. The practical estimate is therefore not submission by December 31, 2027 but full submission-readiness by early autumn of that year, with the final months reserved for administrative acceptance and contingency.

2. Legal basis

The closing date for national applications does not stand alone; it is anchored in a chain of international and domestic acts, each with its own role and date. The table below sets out the instruments that together define the window.

3. Expert insights

Insight one: the mechanism behind four successive postponements deserves attention. The switch-over point originally set by Article 11 of the 2014 Agreement has moved repeatedly: from December 31, 2021 to December 31, 2026, and now to December 31, 2027. The common driver behind each postponement has been member-state concern that the switch would cause shortages in certain product categories. Understanding this mechanism has more predictive value than memorizing any single date: as long as supply-security concerns persist, further adjustment remains a live possibility, and monitoring the Eurasian Economic Commission agenda is part of responsible planning.

Insight two: provisional application and formal entry into force must be read separately. The protocol applies provisionally 10 days after its signing; formal entry into force requires the last written notification that all member states have completed their domestic procedures. Even though Belarus completed parliamentary ratification on June 3, 2026, this cannot be taken as evidence that the protocol is in force for all member states. For an application filed in the interim, the practical estimate of the applicable regime should be documented at the moment of submission, because the legal characterization may differ from the situation at approval.

Insight three: the domestic entry clauses are synchronized with the deadlines. On the Russian side, Resolution No. 2214 extends the validity of Resolution No. 1684 until December 31, 2028, while expressly providing that пп. 63, 87, 101 apply only until December 31, 2027. Domestic rules therefore do not lapse automatically by date; instead, this clause combination implements the policy of closing the door to new applications while keeping existing certificates manageable. Reading only one of the two clauses produces a wrong conclusion about either new filings or legacy maintenance.

It is also worth noting what the window does not change. Certificates already issued under Resolution No. 1684 continue on their own terms after 2027, and maintenance activities for those certificates run while the rules remain in force until December 31, 2028. The window therefore closes only one door: the door to new national applications. Manufacturers sometimes over-generalize the deadline into an exit date for the entire national framework, which distorts planning for renewals, changes and register updates on existing products. Keeping the two temporal boundaries distinct — access versus maintenance — prevents both premature panic and false comfort, and it is the foundation for a migration schedule that spreads Union-pathway work across 2026 and 2027 instead of compressing it into the final year.

4. Practical recommendations

1. Back-plan from December 31, 2027 as a product-line-level hard constraint: identify which products must be submitted within the window and which can move directly to the Union pathway. Assign owners and submission months now, not in 2027, so that testing and clinical work can be sequenced realistically against the statutory durations.
2. For products that miss the window, do not wait for another postponement: re-plan directly under Union rules. Any additional delay scenario should be treated as an upside contingency, never as the baseline, because planning against a further extension leaves no recovery path if the extension does not materialize.
3. Avoid committing in commercial contracts and tender documents to long-term supply under Russian national rules; use more neutral wording. Supply commitments should be tied to holding valid registration, whatever pathway it was obtained through, so that the 2028 regime change does not create contractual breach exposure.

5. Verification checklist

• □ The product grouping has a completed submission plan dated before December 31, 2027
• □ The status of the protocol (provisionally applied / in force) at the intended submission date has been confirmed
• □ The validity provisions of Resolution No. 2214 for пп. 63, 87, 101 have been checked
• □ The feasibility assessment for the Union pathway (reference states, recognizing states, evidence) has been completed
• □ External commitment wording has been adjusted to reflect the window

Regulatory information verified as of October 29, 2026.

GRZAN supports medical device manufacturers entering the Russian market with end-to-end regulatory services covering both registration pathways: national registration under ПП РФ No. 1684, including route selection among clauses 63, 87 and 101, and EAEU registration under ЕЭК Decision No. 46, together with classification strategy support under Decision No. 173 as amended. Our team helps define the optimal route for each registration unit, prepare dossiers and testing plans, coordinate with RZN and expert institutions, and track transition deadlines through December 31, 2027. For tailored support on Russia market entry, pathway selection and dossier preparation, contact GRZAN at info@grzanglobal.com.